BACKGROUND: Colorectal cancers (CRCs) may be categorised according to the degree of microsatellite instability (MSI) exhibited, as MSI-high (MSI-H), MSI-low (MSI-L), or microsatellite stable (MSS). MSI-H status confers a survival advantage to patients with sporadic CRC. AIMS: To determine if low levels of MSI are related to the clinicopathological features and prognosis of sporadic stage C CRC. PATIENTS: A total of 255 patients who underwent resection for sporadic stage C CRC were studied. No patient received chemotherapy. Minimum follow up was five years. METHODS: DNA extracted from archival malignant and non-malignant tissue was amplified by polymerase chain reaction using a panel of 11 microsatellites. MSI-H was defined as instability at > or =40% of markers, MSS as no instability, and MSI-L as instability at >0% but <40% of markers. Patients with MSI-H CRC were excluded from analysis as they have previously been shown to have better survival. RESULTS: Thirty three MSI-L and 176 MSS CRCs were identified. There was no difference in biological characteristics or overall survival of MSI-L compared with MSS CRC but MSI-L was associated with poorer cancer specific survival (hazard ratio 2.0 (95% confidence interval 1.1-3.6)). CONCLUSIONS: Sporadic MSI-L and MSS CRCs have comparable clinicopathological features. Further studies are required to assess the impact of MSI-L on prognosis.
BACKGROUND:Colorectal cancers (CRCs) may be categorised according to the degree of microsatellite instability (MSI) exhibited, as MSI-high (MSI-H), MSI-low (MSI-L), or microsatellite stable (MSS). MSI-H status confers a survival advantage to patients with sporadic CRC. AIMS: To determine if low levels of MSI are related to the clinicopathological features and prognosis of sporadic stage C CRC. PATIENTS: A total of 255 patients who underwent resection for sporadic stage C CRC were studied. No patient received chemotherapy. Minimum follow up was five years. METHODS: DNA extracted from archival malignant and non-malignant tissue was amplified by polymerase chain reaction using a panel of 11 microsatellites. MSI-H was defined as instability at > or =40% of markers, MSS as no instability, and MSI-L as instability at >0% but <40% of markers. Patients with MSI-H CRC were excluded from analysis as they have previously been shown to have better survival. RESULTS: Thirty three MSI-L and 176 MSS CRCs were identified. There was no difference in biological characteristics or overall survival of MSI-L compared with MSS CRC but MSI-L was associated with poorer cancer specific survival (hazard ratio 2.0 (95% confidence interval 1.1-3.6)). CONCLUSIONS: Sporadic MSI-L and MSS CRCs have comparable clinicopathological features. Further studies are required to assess the impact of MSI-L on prognosis.
Authors: Jeremy R Jass; Vicki L J Whitehall; Joanne Young; Barbara Leggett; Stephen J Meltzer; Nagahide Matsubara; Richard Fishel Journal: Cancer Res Date: 2002-10-15 Impact factor: 12.701
Authors: Sarah Halford; Peter Sasieni; Andrew Rowan; Harpreet Wasan; Walter Bodmer; Ian Talbot; Nicholas Hawkins; Robyn Ward; Ian Tomlinson Journal: Cancer Res Date: 2002-01-01 Impact factor: 12.701
Authors: J R Jass; K G Biden; M C Cummings; L A Simms; M Walsh; E Schoch; S J Meltzer; C Wright; J Searle; J Young; B A Leggett Journal: J Clin Pathol Date: 1999-06 Impact factor: 3.411
Authors: Päivi Laiho; Virpi Launonen; Päivi Lahermo; Manel Esteller; Mingzhou Guo; James G Herman; Jukka-Pekka Mecklin; Heikki Järvinen; Pertti Sistonen; Kyoung-Mee Kim; Darryl Shibata; Richard S Houlston; Lauri A Aaltonen Journal: Cancer Res Date: 2002-02-15 Impact factor: 12.701
Authors: W S Samowitz; K Curtin; K N Ma; D Schaffer; L W Coleman; M Leppert; M L Slattery Journal: Cancer Epidemiol Biomarkers Prev Date: 2001-09 Impact factor: 4.254
Authors: J G Herman; A Umar; K Polyak; J R Graff; N Ahuja; J P Issa; S Markowitz; J K Willson; S R Hamilton; K W Kinzler; M F Kane; R D Kolodner; B Vogelstein; T A Kunkel; S B Baylin Journal: Proc Natl Acad Sci U S A Date: 1998-06-09 Impact factor: 11.205
Authors: Kathleen M Murphy; Shengle Zhang; Tanya Geiger; Michael J Hafez; Jeff Bacher; Karin D Berg; James R Eshleman Journal: J Mol Diagn Date: 2006-07 Impact factor: 5.568
Authors: Gianluigi Mazzoccoli; Valerio Pazienza; Anna Panza; Maria Rosa Valvano; Giorgia Benegiamo; Manlio Vinciguerra; Angelo Andriulli; Ada Piepoli Journal: J Cancer Res Clin Oncol Date: 2011-12-24 Impact factor: 4.553